Using CGM to Optimize Diabetes Management and Improve Clinical Outcomes

Diab UKPDS 35 confirmed that every 1% reduction in HbA1c significantly reduced the risk of microvascular complications by 37%, myocardial infarction by 14%, stroke by 12%, and diabetes-related death by 21%. Early achievement of HbA1c < 6.5% after diagnosis of type 2 diabetes (T2DM) significantly reduces the risk of long-term complications and mortality.Compared with traditional […]

iCGM Emerges as the New Standard for Glucose Monitoring

In recent years, with the continuous maturation of fingerstick-calibration-free continuous glucose monitoring (CGM) systems, especially the promotion and application of high-standard integrated CGM (iCGM), glucose monitoring technology is advancing toward a new stage of greater precision.CGM helps people with diabetes better manage their condition. However, different CGM systems vary in clinical outcomes and patient safety.Mean […]

Do You Understand Thyroid Hormone Markers?

Thyroid hormones play a critical role in the maturation of the cerebral cortex, especially in the development, differentiation, and functional maturation of the fetal nervous system.Insufficient thyroid hormone during the fetal and neonatal periods can lead to intellectual disability, deafness, and cretinism; in children, it causes growth retardation; in adults, it results in memory loss […]

How to Drink Tea Properly for People with Diabetes

Tea offers many health benefits, but how should you drink it correctly?Keep in mind the “Three Rules” for drinking tea:Rule 1: Avoid strong tea; drink light tea in moderationTannic acid in strong tea binds to iron and protein like glue, preventing absorption. Over time, this may lead to anemia or stomach discomfort.Do not drink excessive […]

How Should People with Diabetes Choose Among Different Types of Tea?

Tea can be classified into many types according to the degree of fermentation, and the content of bioactive components varies among different teas. People with diabetes can choose the right tea based on their personal needs and physical condition. However, no matter how beneficial tea is, it cannot replace medication. Proper tea drinking is only […]

Professor Andreas Liebl, Diabetes and Metabolism Center Bad Heilbrunn, Germany:New Advances Are Improving Patient Management

In recent years, numerous studies have emerged on the management of type 2 diabetes mellitus (T2DM) and obesity.According to Professor Andreas Liebl, the most noteworthy advances currently come from the development of a new generation of incretin-based drugs, including GLP‑1 receptor agonists, GIP receptor agonists, and in the future, possibly even triple agonists that also […]

Professor Andreas Liebl, Diabetes and Metabolism Center Bad Heilbrunn, Germany:New Management Approaches Address Patients’ Actual Barriers

Despite the growing body of evidence, many patients still face challenges such as poor treatment adherence and difficulty maintaining weight loss.Professor Andreas Liebl states:Indeed, I have encountered many patients who struggle greatly with weight loss even when we provide full support.In my opinion, one of the keys to success is to build an integrated multidisciplinary […]

Professor Andreas Liebl, Diabetes and Metabolism Center Bad Heilbrunn, Germany:Populations for Whom Weight Loss‑Centered Treatment Strategies Should Be Prioritized

Obesity has been recognized as one of the core therapeutic targets in type 2 diabetes mellitus (T2DM).Professor Andreas Liebl emphasizes that weight control itself is an independent therapeutic goal.However, given limited medical resources, it is essential to define priority populations.In his view, the following patient groups should receive prioritized intervention:First group: Early‑stage diabetes patients with […]

Professor Andreas Liebl (Diabetes and Metabolism Center Bad Heilbrunn, Germany): Reshaping the Future Landscape of T2DM and Obesity Management

Professor Andreas Liebl from the Diabetes and Metabolism Center Bad Heilbrunn, Germany, believes that the iteration and upgrading of innovative drugs will be most critical in the coming years. Drugs targeting GLP‑1, GIP, and glucagon receptors will be continuously optimized and diversified. As I noted earlier, such agents allow us to manage patients from a […]